Latest Health News

Page 3 of 271
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026
Humana delivered a better-than-expected third quarter on insurance claims performance, lifting its 2026 adjusted EPS guidance despite reporting an adjusted loss for the period. The company also flagged stronger CenterWell growth and a lower-cost BlackRock joint venture as part of its path towards a 3% pretax margin by 2028.
Ada Torres
Ada Torres
6 Nov 2026
Third Age Health will acquire 75% of New Zealand asbestos specialist Consultex Group for $3.75 million, adding a new Testing, Inspection & Compliance vertical. The deal will be funded through existing cash and bank debt, with settlement expected by 30 November 2026.
Victor Sage
Victor Sage
6 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
BTC Health has expanded its exclusive ExoVasc PEARS distribution rights from Australia into India under a new five-year agreement. The opportunity is potentially significant, but Indian sales remain dependent on CDSCO import approval.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Solventum has raised its full-year adjusted earnings forecast after a third quarter shaped by the expected reversal of ERP-related advance orders. The healthcare technology company also completed its major system cutovers and reported strong growth in Advanced Wound Care.
Ada Torres
Ada Torres
6 Nov 2026
Zoetis lifted its full-year adjusted earnings outlook after a mixed third quarter, but US companion animal revenue fell 8% amid price sensitivity, competition and generic pressure. The animal health group also reported an 18% drop in GAAP net income and a US$89 million impairment charge.
Ada Torres
Ada Torres
5 Nov 2026
Cardinal Health has lifted its fiscal 2027 earnings outlook after a strong opening quarter, with revenue reaching US$67.5 billion and non-GAAP diluted EPS rising 28%. The healthcare distributor also completed a US$500 million share repurchase and advanced several strategic initiatives.
Ada Torres
Ada Torres
5 Nov 2026
Kimberly-Clark delivered stronger adjusted earnings from continuing operations in the third quarter, but organic sales and adjusted operating profit weakened as China disruption, pricing pressure and costs weighed on results. The company reaffirmed its 2026 outlook while beginning life as a larger consumer-health group after completing its Kenvue acquisition.
Victor Sage
Victor Sage
5 Nov 2026
The Cigna Group raised its 2026 adjusted earnings outlook after third-quarter revenue rose 6%, while pharmacy benefit pressure kept underlying profit broadly flat. The health insurer also unveiled a US$3 billion modernisation and productivity programme targeting longer-term growth.
Ada Torres
Ada Torres
5 Nov 2026

Browse the archive

Full archive